Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.71 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.66 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.66 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.66 |
| ▸ | EGFR | P00533 | 2/20 | 0.63 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.58 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9718167 | 0.87 | NR4A1 (0.70) | MAOBNR4A1NR4A2NR4A3EGFR | |
| SCHEMBL433676 | 0.86 | MAOB (0.65) | MAOBNR4A1NR4A2NR4A3EGFR | |
| SCHEMBL6283205 | 0.86 | EGFR (0.70) | MAOBNR4A1NR4A2NR4A3EGFR | |
| SCHEMBL11377981 | 0.85 | MAOB (0.68) | MAOBNR4A1NR4A2NR4A3EGFR | |
| SCHEMBL11683646 | 0.84 | PTPN1 (0.72) | MAOBNR4A1NR4A2NR4A3EGFR | |
| SCHEMBL2013554 | 0.84 | PARP10 (0.71) | MAOBNR4A1NR4A2NR4A3EGFR | |
| SCHEMBL102983 | 0.84 | RAB9A (0.83) | MAOBNR4A1NR4A2NR4A3EGFR | |
| SCHEMBL27396445 | 0.84 | MAOB (0.66) | MAOBNR4A1NR4A2NR4A3EGFR | |
| SCHEMBL42302 | 0.83 | MAOB (1.00) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| SCHEMBL2294574 | 0.83 | MAOB (0.65) | MAOBNR4A1NR4A2NR4A3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| EP-2694472-A2 | SULFONAMIDE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
| WO-2012137982-A9 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-14 | — | — | WO | disclosed |
| WO-2012137982-A2 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | GRIN2A, GRIN2B, SLC1A2 | MAOB 552/4885NR4A1 247/4885NR4A2 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.